

Freddie Hamdy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8438926/publications.pdf>

Version: 2024-02-01

360
papers

24,683
citations

8732

75
h-index

10127

140
g-index

386
all docs

386
docs citations

386
times ranked

28059
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate-Specific Antigen Testing for Prostate Cancer Screening—Is the Message Getting Through?. <i>JAMA Oncology</i> , 2022, 8, 47.	3.4	3
2	Feasibility and safety of radical prostatectomy for oligometastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligometastases to the bone (TRoMbone) trial. <i>BJU International</i> , 2022, 130, 43-53.	1.3	26
3	Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival. <i>Science Advances</i> , 2022, 8, eabf9096.	4.7	19
4	Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. <i>European Urology</i> , 2022, 82, 201-211.	0.9	2
5	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	9.4	264
6	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 532-541.	2.0	16
7	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021, 12, 1236.	5.8	40
8	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. <i>BMC Urology</i> , 2021, 21, 18.	0.6	3
9	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 714-730.	2.6	16
10	Use of intraoperative fluorescence to enhance robot-assisted radical prostatectomy. <i>Future Oncology</i> , 2021, 17, 1083-1095.	1.1	3
11	Local anaesthetic transperineal (LATP) prostate biopsy using a probe-mounted transperineal access system: a multicentre prospective outcome analysis. <i>BJU International</i> , 2021, 128, 311-318.	1.3	28
12	Identification of a serum biomarker signature associated with metastatic prostate cancer. <i>Proteomics - Clinical Applications</i> , 2021, 15, 2000025.	0.8	3
13	Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. <i>British Journal of Cancer</i> , 2021, 125, 534-546.	2.9	8
14	A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease. <i>European Urology Oncology</i> , 2021, 4, 358-369.	2.6	16
15	Intermediate-risk Prostate Cancer—A Sheep in Wolf's Clothing?. <i>European Urology Oncology</i> , 2021, , .	2.6	0
16	Placebo comparator group selection and use in surgical trials: the ASPIRE project including expert workshop. <i>Health Technology Assessment</i> , 2021, 25, 1-52.	1.3	6
17	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1618-1631.	5.1	48
18	Prostate-Specific Membrane Antigen—Guided Surgery. <i>Journal of Nuclear Medicine</i> , 2020, 61, 6-12.	2.8	31

#	ARTICLE	IF	CITATIONS
19	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. <i>BJU International</i> , 2020, 125, 506-514.	1.3	32
20	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. <i>European Urology</i> , 2020, 77, 320-330.	0.9	107
21	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. <i>Nature Communications</i> , 2020, 11, 3905.	5.8	28
22	Outreach and Influence of Surgical Societies'™ Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemic'™ An Anonymized International Urologic Expert Inquiry. <i>Urology</i> , 2020, 145, 73-78.	0.5	2
23	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , 2020, 123, 1063-1070.	2.9	15
24	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. <i>BMJ Open</i> , 2020, 10, e036024.	0.8	7
25	A new Editorial Team for the <i>BJU International</i> . <i>BJU International</i> , 2020, 126, 213-214.	1.3	0
26	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , 2020, 28, 1467-1475.	1.4	14
27	Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. <i>Cancer Causes and Control</i> , 2020, 31, 431-449.	0.8	53
28	Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines). <i>Lancet</i> , The, 2020, 395, 828-838.	6.3	54
29	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1731-1738.	1.1	27
30	Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. <i>British Journal of Cancer</i> , 2020, 123, 1089-1100.	2.9	51
31	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. , 2020, 8, e000928.		27
32	Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit - the 'Fry-Turnbull'™ effect. <i>BJU International</i> , 2020, 125, 484-486.	1.3	4
33	Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 652-669.	1.2	6
34	Transcriptomic and Functional Screens Reveal MicroRNAs That Modulate Prostate Cancer Metastasis. <i>Frontiers in Oncology</i> , 2020, 10, 292.	1.3	6
35	Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2020, 78, 402-414.	0.9	183
36	Glutamine deprivation alters the origin and function of cancer cell exosomes. <i>EMBO Journal</i> , 2020, 39, e103009.	3.5	64

#	ARTICLE	IF	CITATIONS
37	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-176.	1.3	22
38	Prostatic capsular incision during radical prostatectomy has important oncological implications: a systematic review and meta-analysis. <i>BJU International</i> , 2019, 124, 554-566.	1.3	7
39	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 200-213.	2.4	6
40	Mating induces switch from hormone-dependent to hormone-independent steroid receptor-mediated growth in <i>Drosophila</i> secondary cells. <i>PLoS Biology</i> , 2019, 17, e3000145.	2.6	16
41	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	0.9	148
42	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
43	Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. <i>Prostate</i> , 2019, 79, 1079-1089.	1.2	28
44	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF1, IGF1, IGFBP1, IGFBP2 and IGFBP3 in a pooled analysis of 16,024 men from 22 studies. <i>International Journal of Cancer</i> , 2019, 145, 3244-3256.	2.3	14
45	Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. <i>European Urology</i> , 2019, 76, 329-337.	0.9	48
46	Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial. <i>European Journal of Cancer Prevention</i> , 2019, 28, 569-575.	0.6	7
47	A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk. <i>Cancer Research</i> , 2019, 79, 274-285.	0.4	25
48	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 208-216.	1.1	21
49	Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study. <i>Journal of Urology</i> , 2019, 201, 510-519.	0.2	27
50	First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright. <i>European Urology</i> , 2018, 73, 653-655.	0.9	4
51	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 883.	3.8	296
52	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. <i>Cancer Epidemiology</i> , 2018, 52, 99-105.	0.8	8
53	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. <i>Journal of Urology</i> , 2018, 199, 1470-1474.	0.2	11
54	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018, 50, 682-692.	9.4	182

#	ARTICLE	IF	CITATIONS
55	Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient reclassification?. <i>BJU International</i> , 2018, 122, 794-800.	1.3	23
56	Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. <i>Cancer Causes and Control</i> , 2018, 29, 383-388.	0.8	15
57	Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). <i>European Journal of Oncology Nursing</i> , 2018, 32, 73-81.	0.9	17
58	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 35-46.	2.4	16
59	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	2.9	12
60	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ: British Medical Journal</i> , 2018, 360, j5757.	2.4	153
61	Sprouty2 loss-induced IL 6 drives castration-resistant prostate cancer through scavenger receptor B1. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	19
62	Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens. <i>European Urology</i> , 2018, 73, 351-352.	0.9	0
63	Orient Expression: Solving the Mystery of Asian Prostate Cancer?. <i>European Urology</i> , 2018, 73, 340-342.	0.9	3
64	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-424.	0.8	155
65	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018, 9, 4616.	5.8	43
66	ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 687-696.	0.7	32
67	Time for a "Radical" Change to Active Surveillance for Prostate Cancer?. <i>European Urology</i> , 2018, 74, 281-282.	0.9	4
68	Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. <i>Trials</i> , 2018, 19, 50.	0.7	48
69	Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage. <i>Cancer Research</i> , 2018, 78, 3497-3509.	0.4	44
70	AA9int: SNP interaction pattern search using non-hierarchical additive model set. <i>Bioinformatics</i> , 2018, 34, 4141-4150.	1.8	3
71	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	9.4	652
72	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	5.8	88

#	ARTICLE	IF	CITATIONS
73	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. <i>BJU International</i> , 2018, 122, 970-977.	1.3	17
74	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-96.	1.3	33
75	SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns. <i>Bioinformatics</i> , 2017, 33, 822-833.	1.8	11
76	In Defense of Randomized Clinical Trials in Surgery: Let Us Not Forget Archie Cochrane's Legacy. <i>European Urology</i> , 2017, 71, 820-821.	0.9	4
77	10-Year Outcomes in Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 178-181.	13.9	16
78	Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. <i>European Urology</i> , 2017, 72, 345-351.	0.9	16
79	Understanding and Improving Recruitment to Randomised Controlled Trials: Qualitative Research Approaches. <i>European Urology</i> , 2017, 72, 789-798.	0.9	105
80	Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1121.	3.8	15
81	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. <i>British Journal of Cancer</i> , 2017, 117, 734-743.	2.9	7
82	Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP). <i>BMJ Open</i> , 2017, 7, e015994.	0.8	11
83	Systematic Review of Studies Reporting Positive Surgical Margins After Bladder Neck Sparing Radical Prostatectomy. <i>Current Urology Reports</i> , 2017, 18, 99.	1.0	34
84	Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial. <i>Cancer Causes and Control</i> , 2017, 28, 877-888.	0.8	2
85	Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. <i>Journal of Urology</i> , 2017, 197, 607-613.	0.2	18
86	Prostate cancer risk related to foods, food groups, macronutrients and micronutrients derived from the UK Dietary Cohort Consortium food diaries. <i>European Journal of Clinical Nutrition</i> , 2017, 71, 274-283.	1.3	28
87	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017, 71, 381-388.	0.9	41
88	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. <i>International Journal of Cancer</i> , 2017, 140, 75-85.	2.3	28
89	Reducing Mortality in the Ageing Patient: Treatment of the Primary Tumour Is Not Necessary. <i>European Urology Focus</i> , 2017, 3, 328-329.	1.6	0
90	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. <i>PLoS Genetics</i> , 2017, 13, e1007001.	1.5	34

#	ARTICLE	IF	CITATIONS
91	Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. <i>BMJ Open</i> , 2017, 7, e017729.	0.8	27
92	Identifying Ureters In Situ Under Fluorescence During Laparoscopic and Open Colorectal Surgery. <i>Annals of Surgery</i> , 2016, 263, e1-e2.	2.1	40
93	Prostate-specific antigen patterns in <scp>US</scp> and European populations: comparison of six diverse cohorts. <i>BJU International</i> , 2016, 118, 911-918.	1.3	5
94	<i>PALB2</i>,<i>CHEK2</i>and<i>ATM</i>rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174
95	Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised trial of PSA testing for Prostate cancer (CAP). <i>BMJ Open</i> , 2016, 6, e011063.	0.8	23
96	Novel biomarkers for the detection of prostate cancer. <i>Journal of Clinical Urology</i> , 2016, 9, 3-10.	0.1	24
97	The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?. <i>BJU International</i> , 2016, 118, 843-843.	1.3	5
98	Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. <i>European Urology</i> , 2016, 70, 941-951.	0.9	46
99	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. <i>Oncologist</i> , 2016, 21, 716-722.	1.9	27
100	Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. <i>International Journal of Cancer</i> , 2016, 139, 1520-1533.	2.3	26
101	Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. <i>BJU International</i> , 2016, 117, E10-9.	1.3	120
102	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1415-1424.	13.9	2,101
103	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1425-1437.	13.9	962
104	Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. <i>BJU International</i> , 2016, 118, 869-879.	1.3	52
105	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	7.7	157
106	Investigating the prostate specific antigen, body mass index and age relationship: is an age-adjusted BMI-adjusted PSA model clinically useful?. <i>Cancer Causes and Control</i> , 2016, 27, 1465-1474.	0.8	17
107	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , 2016, 7, 10979.	5.8	50
108	Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. <i>British Journal of Cancer</i> , 2016, 115, 90-94.	2.9	38

#	ARTICLE	IF	CITATIONS
109	Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. <i>Trials</i> , 2016, 17, 497.	0.7	5
110	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. <i>BMC Medicine</i> , 2016, 14, 66.	2.3	42
111	Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1875-1891.	0.7	7
112	Misclassification of outcome in case-control studies: Methods for sensitivity analysis. <i>Statistical Methods in Medical Research</i> , 2016, 25, 2377-2393.	0.7	23
113	Insertion of an SVA-E retrotransposon into the <i>CASP8</i> gene is associated with protection against prostate cancer. <i>Human Molecular Genetics</i> , 2016, 25, 1008-1018.	1.4	22
114	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. <i>Cancer Research</i> , 2016, 76, 2288-2300.	0.4	117
115	DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair. <i>Cancer Research</i> , 2016, 76, 1078-1088.	0.4	71
116	Validation of the Hospital Episode Statistics Outpatient Dataset in England. <i>Pharmacoeconomics</i> , 2016, 34, 161-168.	1.7	29
117	Regulation of Dense-Core Granule Replenishment by Autocrine BMP Signalling in <i>Drosophila</i> Secondary Cells. <i>PLoS Genetics</i> , 2016, 12, e1006366.	1.5	29
118	Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer. <i>Oncotarget</i> , 2016, 7, 1107-1119.	0.8	5
119	Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial. <i>BMJ Open</i> , 2015, 5, e008953.	0.8	18
120	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , 2015, 75, 1467-1474.	1.2	54
121	Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification. <i>International Journal of Cancer</i> , 2015, 137, 1509-1515.	2.3	25
122	Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. <i>Cancer Causes and Control</i> , 2015, 26, 205-218.	0.8	33
123	Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. <i>European Urology</i> , 2015, 67, 993-1005.	0.9	96
124	Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. <i>Annals of Oncology</i> , 2015, 26, 756-761.	0.6	85
125	The Genomic Diversity of Prostate Cancer: Our Achilles Heel Explored. <i>European Urology</i> , 2015, 67, 823-824.	0.9	4
126	Variation between specialist uropathologists in reporting extraprostatic extension after radical prostatectomy. <i>Journal of Clinical Pathology</i> , 2015, 68, 465-472.	1.0	7

#	ARTICLE	IF	CITATIONS
127	Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised trial of PSA testing for) Tj ETQq1 1 0.784314 rgBT /@verlock	1.1	10
128	Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. <i>European Urology</i> , 2015, 67, 904-912.	0.9	18
129	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1121-1129.	1.1	56
130	Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. <i>BMC Health Services Research</i> , 2015, 15, 80.	0.9	16
131	Identification and Diagnostic Performance of a Small RNA within the PCA3 and BMCC1 Gene Locus That Potentially Targets mRNA. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 268-275.	1.1	10
132	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. <i>Cancer Causes and Control</i> , 2015, 26, 1603-1616.	0.8	77
133	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015, 24, 5589-5602.	1.4	67
134	Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair. <i>Science Translational Medicine</i> , 2015, 7, 312re11.	5.8	73
135	Gleason drift in the <sc>NIHR P</sc>otec<sc>T</sc> study. <i>Histopathology</i> , 2015, 66, 438-446.	1.6	9
136	Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 1142-1157.	2.2	107
137	Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	146
138	Genome-Wide Association Study of Prostate Cancer – Specific Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1796-1800.	1.1	27
139	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. <i>Genetics in Medicine</i> , 2015, 17, 789-795.	1.1	87
140	Prostate cancer cells home to bone using a novel <i>in vivo</i> model: Modulation by the integrin antagonist GLPG0187. <i>International Journal of Cancer</i> , 2015, 136, 1731-1740.	2.3	10
141	Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. <i>PLoS ONE</i> , 2015, 10, e0136735.	1.1	6
142	Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study. <i>Health Services and Delivery Research</i> , 2015, 3, 1-138.	1.4	4
143	Polymorphisms of an Innate Immune Gene, Toll-Like Receptor 4, and Aggressive Prostate Cancer Risk: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e110569.	1.1	24
144	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. <i>PLoS Genetics</i> , 2014, 10, e1004129.	1.5	34

#	ARTICLE	IF	CITATIONS
145	PROSPECTIVâ€”a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial: TableÂ1. <i>BMJ Open</i> , 2014, 4, e005186.	0.8	10
146	Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies. <i>International Journal of Urology</i> , 2014, 21, 786-792.	0.5	11
147	Adherence to Dietary and Lifestyle Recommendations and Prostate Cancer Risk in the Prostate Testing for Cancer and Treatment (ProtecT) Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2066-2077.	1.1	33
148	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1109-1118.	5.1	205
149	Menâ€™s knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study. <i>BMC Cancer</i> , 2014, 14, 812.	1.1	15
150	Genetic Variation in Prostate-Specific Antigenâ€”Detected Prostate Cancer and the Effect of Control Selection on Genetic Association Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1356-1365.	1.1	26
151	Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2014, 32, 185-191.	1.2	28
152	The Future of Randomised Controlled Trials in Urology. <i>European Urology</i> , 2014, 66, 1-3.	0.9	22
153	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	0.9	195
154	Molecular subtyping of bladder cancer using <sc>K</sc>ohonen selfâ€”organizing maps. <i>Cancer Medicine</i> , 2014, 3, 1225-1234.	1.3	18
155	BMP-regulated exosomes from <i>Drosophila</i> male reproductive glands reprogram female behavior. <i>Journal of Cell Biology</i> , 2014, 206, 671-688.	2.3	128
156	Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences. <i>Trials</i> , 2014, 15, 323.	0.7	50
157	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014, 46, 1103-1109.	9.4	408
158	Prevention and early detection of prostate cancer. <i>Lancet Oncology</i> , The, 2014, 15, e484-e492.	5.1	372
159	The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals. <i>BMC Family Practice</i> , 2014, 15, 81.	2.9	40
160	Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). <i>British Journal of Cancer</i> , 2014, 110, 2829-2836.	2.9	26
161	The intellectual challenges and emotional consequences of equipoise contributed to the fragility of recruitment in six randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 912-920.	2.4	114
162	Reply to Behnam Shakiba's Letter to the Editor re: Philipp Dahm, James Nâ€™Dow, Lars Holmberg, Freddie Hamdy. The Future of Randomised Controlled Trials in Urology. <i>Eur Urol</i> 2014;66:1â€™3. <i>European Urology</i> , 2014, 66, e8.	0.9	0

#	ARTICLE	IF	CITATIONS
163	Men with prostate cancer make positive dietary changes following diagnosis and treatment. <i>Cancer Causes and Control</i> , 2013, 24, 1119-1128.	0.8	36
164	Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. <i>BJU International</i> , 2013, 111, 1148-1155.	1.3	9
165	DNA damage response in peritumoral regions of oesophageal cancer microenvironment. <i>Carcinogenesis</i> , 2013, 34, 139-145.	1.3	18
166	Very Low PSA Concentrations and Deletions of the KLK3 Gene. <i>Clinical Chemistry</i> , 2013, 59, 234-244.	1.5	12
167	Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. <i>Cancer Causes and Control</i> , 2013, 24, 39-45.	0.8	8
168	Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. <i>Cancer Causes and Control</i> , 2013, 24, 323-334.	0.8	30
169	Transurethral resection biopsy as part of a saturation biopsy protocol: A cohort study and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 542-548.	0.8	3
170	Prospective Randomized Evaluation of Risk-adapted Prostate-specific Antigen Screening in Young Men: The PROBASE Trial. <i>European Urology</i> , 2013, 64, 873-875.	0.9	43
171	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , 2013, 45, 385-391.	9.4	492
172	Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 635-643.	0.8	30
173	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. <i>Human Molecular Genetics</i> , 2013, 22, 408-415.	1.4	118
174	Psychological Impact of Prostate Biopsy: Physical Symptoms, Anxiety, and Depression. <i>Journal of Clinical Oncology</i> , 2013, 31, 4235-4241.	0.8	81
175	A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. <i>Human Molecular Genetics</i> , 2013, 22, 5056-5064.	1.4	130
176	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. <i>Human Molecular Genetics</i> , 2013, 22, 2520-2528.	1.4	100
177	Using Genetic Proxies for Lifecourse Sun Exposure to Assess the Causal Relationship of Sun Exposure with Circulating Vitamin D and Prostate Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 597-606.	1.1	22
178	Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. <i>European Journal of Cancer Prevention</i> , 2013, 22, 121-125.	0.6	7
179	The emerging role of histone deacetylase (<sc>HDAC</sc>) inhibitors in urological cancers. <i>BJU International</i> , 2013, 111, 537-542.	1.3	35
180	Alcohol consumption and PSA-detected prostate cancer risk: A case-control nested in the ProtecT study. <i>International Journal of Cancer</i> , 2013, 132, 2176-2185.	2.3	31

#	ARTICLE	IF	CITATIONS
181	The handling and sampling of radical prostatectomy specimens for reporting and research: the Oxford approach. <i>Journal of Clinical Pathology</i> , 2012, 65, 1057-1061.	1.0	12
182	Circulating Insulin-Like Growth Factors and IGF-Binding Proteins in PSA-Detected Prostate Cancer: The Large Caseâ€“Control Study ProtecT. <i>Cancer Research</i> , 2012, 72, 503-515.	0.4	50
183	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. <i>BMJ: British Medical Journal</i> , 2012, 344, d7894-d7894.	2.4	211
184	Associations of Lifestyle Factors and Anthropometric Measures with Repeat PSA Levels During Active Surveillance/Monitoring. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1877-1885.	1.1	19
185	Flexible Cystoscopy Findings in Patients Investigated for Profound Lower Urinary Tract Symptoms, Recurrent Urinary Tract Infection, and Pain. <i>Journal of Endourology</i> , 2012, 26, 1468-1472.	1.1	10
186	Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved: Figure 1. <i>Heart</i> , 2012, 98, 345-348.	1.2	10
187	Bone morphogenetic protein- and mating-dependent secretory cell growth and migration in the <i>Drosophila</i> accessory gland. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 19292-19297.	3.3	49
188	Evaluating Genetic Risk for Prostate Cancer among Japanese and Latinos. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 2048-2058.	1.1	51
189	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. <i>Nature Genetics</i> , 2012, 44, 1326-1329.	9.4	178
190	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2012, 30, 181-187.	1.2	66
191	Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. <i>Cancer Causes and Control</i> , 2012, 23, 1865-1873.	0.8	23
192	Predictors of Attendance for Prostate-Specific Antigen Screening Tests and Prostate Biopsy. <i>European Urology</i> , 2012, 62, 649-655.	0.9	22
193	iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e30885.	1.1	56
194	Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. <i>International Journal of Cancer</i> , 2012, 131, 1187-1196.	2.3	63
195	Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1. <i>Cancer Research</i> , 2012, 72, 2814-2821.	0.4	272
196	Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the Prostate testing for cancer and Treatment study. <i>Cancer Causes and Control</i> , 2012, 23, 575-588.	0.8	20
197	A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. <i>Cancer Causes and Control</i> , 2012, 23, 907-917.	0.8	32
198	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2012, 30, 149-155.	1.2	101

#	ARTICLE	IF	CITATIONS
199	Current Vaccination Strategies for Prostate Cancer. <i>European Urology</i> , 2012, 61, 290-306.	0.9	35
200	Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. <i>Cancer Causes and Control</i> , 2012, 23, 347-354.	0.8	32
201	Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2012, 122, 4025-4036.	3.9	39
202	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011, 43, 1098-1103.	9.4	251
203	A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 628-636.	2.4	18
204	Exploring treatment preferences facilitated recruitment to randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 1127-1136.	2.4	93
205	Long-term quality of life in prostate cancer. <i>Lancet Oncology</i> , The, 2011, 12, 832-833.	5.1	3
206	Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. <i>BJU International</i> , 2011, 108, 1402-1408.	1.3	63
207	Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK. <i>BJU International</i> , 2011, 108, 1409-1414.	1.3	6
208	Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. <i>British Journal of Cancer</i> , 2011, 104, 875-881.	2.9	23
209	MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. <i>European Urology</i> , 2011, 59, 671-681.	0.9	401
210	Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. <i>Human Genetics</i> , 2011, 129, 687-694.	1.8	83
211	Association of diabetes mellitus with prostate cancer: Nested case-control study (Prostate testing) Tj ETQq1 1 0,784314 rgBT /Over 2.3 56		
212	Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: Findings from a large, population-based, case-control study (the ProtecT study). <i>International Journal of Cancer</i> , 2011, 128, 1442-1448.	2.3	41
213	PSA-detected prostate cancer and the potential for dedifferentiation-estimating the proportion capable of progression. <i>International Journal of Cancer</i> , 2011, 128, 1462-1470.	2.3	14
214	Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. <i>Cancer Epidemiology</i> , 2011, 35, 139-144.	0.8	4
215	Acupuncture in urological practice-A survey of urologists in England. <i>Complementary Therapies in Medicine</i> , 2011, 19, 27-31.	1.3	11
216	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. <i>Nature Genetics</i> , 2011, 43, 785-791.	9.4	265

#	ARTICLE	IF	CITATIONS
217	Hypermethylation of CpG Islands and Shores around Specific MicroRNAs and Mirtrons Is Associated with the Phenotype and Presence of Bladder Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1287-1296.	3.2	96
218	Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors. <i>Cancer Research</i> , 2011, 71, 1805-1815.	0.4	111
219	Genome-wide association study identifies new prostate cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2011, 20, 3867-3875.	1.4	160
220	Curative radiation therapy in prostate cancer. <i>Acta Oncologica</i> , 2011, 50, 98-103.	0.8	15
221	Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. <i>British Journal of Cancer</i> , 2011, 105, 931-937.	2.9	18
222	Association between Prostinogen (KLK15) Genetic Variants and Prostate Cancer Risk and Aggressiveness in Australia and a Meta-Analysis of GWAS Data. <i>PLoS ONE</i> , 2011, 6, e26527.	1.1	14
223	The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 316-27.	0.4	9
224	The relation between adiposity throughout the life course and variation in IGFs and IGFFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. <i>Cancer Causes and Control</i> , 2010, 21, 1829-1842.	0.8	26
225	Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts. <i>European Urology</i> , 2010, 57, 446-452.	0.9	12
226	The Application of Artificial Intelligence to Microarray Data: Identification of a Novel Gene Signature to Identify Bladder Cancer Progression. <i>European Urology</i> , 2010, 57, 398-406.	0.9	52
227	Reply to Dennis Morrodâ€™s Letter to the Editor and Fritz H. Schröderâ€™s Reply to Dennis Morrodâ€™s Letter to the Editor re: Monique J. Roobol, Ewout W. Steyerberg, Ries Kranse, et al. A Risk-Based Strategy Improves Prostate-Specific Antigenâ€™Driven Detection of Prostate Cancer. <i>Eur Urol</i> 2010;57:79â€™85. <i>European Urology</i> , 2010, 58, 329-330.	0.9	0
228	Re: Mortality Results From the Göteborg Randomised Population-Based Prostate-Cancer Screening Trial. <i>European Urology</i> , 2010, 58, 940-941.	0.9	1
229	Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. <i>Prostate</i> , 2010, 70, 875-882.	1.2	65
230	Eightâ€™plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study. <i>Prostate</i> , 2010, 70, 1313-1332.	1.2	46
231	Mutation analysis of the MSMB gene in familial prostate cancer. <i>British Journal of Cancer</i> , 2010, 102, 414-418.	2.9	19
232	Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. <i>British Journal of Cancer</i> , 2010, 102, 1335-1340.	2.9	77
233	Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. <i>Science Translational Medicine</i> , 2010, 2, 62ra92.	5.8	140
234	Androgen Regulates ADAMTS15 Gene Expression in Prostate Cancer Cells. <i>Cancer Investigation</i> , 2010, 28, 698-710.	0.6	15

#	ARTICLE	IF	CITATIONS
235	Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2833-2838.	1.1	20
236	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , 2010, 16, 4374-4381.	3.2	86
237	Targeting chemotherapy to advanced bladder cancer patients most likely to benefit. <i>Future Oncology</i> , 2010, 6, 193-196.	1.1	1
238	High Aldehyde Dehydrogenase Activity Identifies Tumor-Initiating and Metastasis-Initiating Cells in Human Prostate Cancer. <i>Cancer Research</i> , 2010, 70, 5163-5173.	0.4	351
239	Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12 Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1632-1642.	1.1	142
240	Evaluation of Association of HNF1B Variants with Diverse Cancers: Collaborative Analysis of Data from 19 Genome-Wide Association Studies. <i>PLoS ONE</i> , 2010, 5, e10858.	1.1	28
241	Associations between an Obesity Related Genetic Variant (FTO rs9939609) and Prostate Cancer Risk. <i>PLoS ONE</i> , 2010, 5, e13485.	1.1	61
242	A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the Tj ETQq0 0 OrgBT /Overclock 10 T		
243	Metabolic imbalance and prostate cancer progression. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2010, 1, 248-71.	0.4	11
244	Neurofuzzy Modeling to Determine Recurrence Risk Following Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of the Bladder. <i>Clinical Cancer Research</i> , 2009, 15, 3150-3155.	3.2	24
245	PTGS2â€“899G>C and prostate cancer risk: a population-based nested caseâ€“control study (ProtecT) and a systematic review with meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 296-300.	2.0	16
246	Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer. <i>Cancer Research</i> , 2009, 69, 8472-8481.	0.4	291
247	Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. <i>British Journal of Cancer</i> , 2009, 100, 1198-1204.	2.9	58
248	A recurrent truncating germline mutation in the BRIP1/FANCI gene and susceptibility to prostate cancer. <i>British Journal of Cancer</i> , 2009, 100, 426-430.	2.9	57
249	Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research. <i>Journal of Health Services Research and Policy</i> , 2009, 14, 77-81.	0.8	16
250	Stage Shift in Psa-detected Prostate Cancers â€“ Effect Modification by Gleason Score. <i>Journal of Medical Screening</i> , 2009, 16, 98-101.	1.1	19
251	LYRIC/AEG-1 Is Targeted to Different Subcellular Compartments by Ubiquitinylation and Intrinsic Nuclear Localization Signals. <i>Clinical Cancer Research</i> , 2009, 15, 3003-3013.	3.2	75
252	Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2874-2881.	1.1	64

#	ARTICLE	IF	CITATIONS
253	Association of Folate-Pathway Gene Polymorphisms with the Risk of Prostate Cancer: a Population-Based Nested Case-Control Study, Systematic Review, and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2528-2539.	1.1	89
254	It's not just what you say, it's also how you say it: Opening the "black box" of informed consent appointments in randomised controlled trials. <i>Social Science and Medicine</i> , 2009, 68, 2018-2028.	1.8	154
255	FGFR3 Mutations Indicate Better Survival in Invasive Upper Urinary Tract and Bladder Tumours. <i>European Urology</i> , 2009, 55, 650-658.	0.9	110
256	Life course sun exposure and risk of prostate cancer: Population-based nested case-control study and meta-analysis. <i>International Journal of Cancer</i> , 2009, 125, 1414-1423.	2.3	49
257	Prostate cancer proteomics: The urgent need for clinically validated biomarkers. <i>Proteomics - Clinical Applications</i> , 2009, 3, 197-212.	0.8	9
258	Identification of new genetic risk factors for prostate cancer. <i>Asian Journal of Andrology</i> , 2009, 11, 49-55.	0.8	23
259	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. <i>Nature Genetics</i> , 2009, 41, 1116-1121.	9.4	389
260	Multiple loci on 8q24 associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2009, 41, 1058-1060.	9.4	273
261	Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. <i>British Journal of Cancer</i> , 2009, 101, 390-394.	2.9	17
262	Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. <i>BJU International</i> , 2009, 104, 1592-1598.	1.3	69
263	Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?. <i>European Journal of Cancer</i> , 2009, 45, 2569-2573.	1.3	18
264	Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: A case-control study nested within the UK population-based ProtecT (Prostate testing for) Tj ETQq0 0 0 rgBIL3 Overloads 10 Tf 50		
265	Psychological distress and prostate specific antigen levels in men with and without prostate cancer. <i>Brain, Behavior, and Immunity</i> , 2009, 23, 1073-1078.	2.0	6
266	Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 29-36.	2.4	133
267	Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 67-73.	2.4	12
268	Predictive modeling in cancer: where systems biology meets the stock market. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 867-870.	1.1	9
269	Screening for prostate cancer remains controversial. <i>Lancet, The</i> , 2009, 374, 1482-1483.	6.3	22
270	Trends in Prostate Cancer Screening: Overview of the UK. , 2009, , 15-21.		4

#	ARTICLE	IF	CITATIONS
271	Prostate cancer cells home to bone in a new in vivo model of bone metastasis. <i>FASEB Journal</i> , 2009, 23, 927-111.	0.2	1
272	Management of low-risk prostate cancer. <i>World Journal of Urology</i> , 2008, 26, 411-414.	1.2	2
273	The spectrum of prostate cancer care: From curative intent to palliation. <i>Current Prostate Reports</i> , 2008, 6, 56-63.	0.1	0
274	Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. <i>Prostate</i> , 2008, 68, 661-674.	1.2	51
275	Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. <i>International Journal of Cancer</i> , 2008, 122, 952-956.	2.3	77
276	Similar Treatment Outcomes for Radical Cystectomy and Radical Radiotherapy in Invasive Bladder Cancer Treated at a United Kingdom Specialist Treatment Center: In Regard to Kotwal et al. (<i>Int J Radiat Oncol Biol Phys</i>) 71, 1601-1602.	0.4	1
277	Multiple newly identified loci associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2008, 40, 316-321.	9.4	796
278	Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. <i>BJU International</i> , 2008, 101, 547-555.	1.3	53
279	A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. <i>BJU International</i> , 2008, 101, 1448-1453.	1.3	49
280	Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. <i>BJU International</i> , 2008, 102, 1400-1406.	1.3	41
281	Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?. <i>BJU International</i> , 2008, 102, 1629-1633.	1.3	10
282	Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial. <i>European Urology</i> , 2008, 53, 1186-1193.	0.9	41
283	Screening for Prostate Cancer: An Update. <i>European Urology</i> , 2008, 53, 37-44.	0.9	43
284	Contribution of a Single Repeat PSA Test to Prostate Cancer Risk Assessment: Experience from the ProtecT Study. <i>European Urology</i> , 2008, 53, 777-784.	0.9	19
285	iTRAQ-Facilitated Proteomic Analysis of Human Prostate Cancer Cells Identifies Proteins Associated with Progression. <i>Journal of Proteome Research</i> , 2008, 7, 897-907.	1.8	110
286	Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. <i>Lancet Oncology</i> , The, 2008, 9, 445-452.	5.1	231
287	What are the practitioner-level determinants for inappropriate PSA testing?. <i>Nature Reviews Urology</i> , 2008, 5, 70-71.	1.4	0
288	Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group. <i>Journal of Medical Ethics</i> , 2008, 34, 37-40.	1.0	26

#	ARTICLE	IF	CITATIONS
289	Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2052-2061.	1.1	148
290	Height and Prostate Cancer Risk: A Large Nested Case-Control Study (Protect) and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2325-2336.	1.1	83
291	Multiple Loci With Different Cancer Specificities Within the 8q24 Gene Desert. <i>Journal of the National Cancer Institute</i> , 2008, 100, 962-966.	3.0	306
292	<i>Epidemiology, Pathology and Pathogenesis.</i> , 2008, , 451-469.		13
293	Phenol Sulfotransferase SULT1A1*2 Allele and Enhanced Risk of Upper Urinary Tract Urothelial Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2500-2503.	1.1	24
294	Gene Expression Assays. <i>Advances in Clinical Chemistry</i> , 2007, 44, 247-292.	1.8	32
295	Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage. <i>Clinical Cancer Research</i> , 2007, 13, 1720-1725.	3.2	139
296	Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 2046-2053.	3.2	163
297	Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2007, 335, 1139.	2.4	18
298	Lack of Noggin Expression by Cancer Cells Is a Determinant of the Osteoblast Response in Bone Metastases. <i>American Journal of Pathology</i> , 2007, 170, 160-175.	1.9	93
299	Application of Artificial Intelligence to the Management of Urological Cancer. <i>Journal of Urology</i> , 2007, 178, 1150-1156.	0.2	89
300	The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: Implications for association studies with human cancers. <i>International Journal of Cancer</i> , 2007, 121, 1958-1966.	2.3	6
301	DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer. <i>Prostate</i> , 2007, 67, 341-347.	1.2	16
302	Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. <i>Prostate</i> , 2007, 67, 1761-1769.	1.2	55
303	Clinically localised prostate cancer is microsatellite stable. <i>BJU International</i> , 2007, 99, 1031-1035.	1.3	13
304	The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme. <i>BJU International</i> , 2007, 100, 514-517.	1.3	10
305	Combination of Polymorphisms From Genes Related to Estrogen Metabolism and Risk of Prostate Cancers: The Hidden Face of Estrogens. <i>Journal of Clinical Oncology</i> , 2007, 25, 3596-3602.	0.8	89
306	The spectrum of prostate cancer care: From curative intent to palliation. <i>Current Urology Reports</i> , 2007, 8, 245-252.	1.0	5

#	ARTICLE	IF	CITATIONS
307	Continuing Controversy Over Monitoring Men With Localized Prostate Cancer: A Systematic Review of Programs in the Prostate Specific Antigen Era. <i>Journal of Urology</i> , 2006, 176, 439-449.	0.2	45
308	Neuro-Fuzzy Modeling: An Accurate and Interpretable Method for Predicting Bladder Cancer Progression. <i>Journal of Urology</i> , 2006, 175, 474-479.	0.2	32
309	Multifocal Urothelial Cancers With the Mutator Phenotype are of Monoclonal Origin and Require Panurothelial Treatment for Tumor Clearance. <i>Journal of Urology</i> , 2006, 175, 2323-2330.	0.2	58
310	A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). <i>Contemporary Clinical Trials</i> , 2006, 27, 413-419.	0.8	22
311	Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. <i>BJU International</i> , 2006, 98, 777-782.	1.3	40
312	Re: Incidence of Initial Local Therapy Among Men with Lower-Risk Prostate Cancer in the United States. <i>European Urology</i> , 2006, 50, 1368-1370.	0.9	0
313	A model of the natural history of screen-detected prostate cancer. <i>British Journal of Cancer</i> , 2006, 95, 1122-1123.	2.9	4
314	472: The Value of Repeat Serum PSA Measurements in the Detection of Prostate Cancer - Experience from the Feasibility Phase of the UK Protec Study. <i>Journal of Urology</i> , 2006, 175, 153-153.	0.2	4
315	Bone-Directed Therapy in Prostate Cancer: Rationale and Novel Approaches. <i>Translational Medicine Series</i> , 2006, , 223-236.	0.0	0
316	Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of ≤ 10 ng/ml: Systematic Review and Meta-Analysis. <i>European Urology</i> , 2005, 48, 386-399.	0.9	222
317	Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. <i>Prostate</i> , 2005, 65, 322-330.	1.2	52
318	Screening for Prostate Cancer. , 2005, , 31-40.		0
319	Promoter Hypermethylation Is Associated With Tumor Location, Stage, and Subsequent Progression in Transitional Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 2903-2910.	0.8	273
320	Prognostic value of serum markers for prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 64-81.	1.4	63
321	Can androgen receptor levels in the prostate predict non-organ-confined prostate cancer?. <i>Nature Reviews Urology</i> , 2005, 2, 368-369.	1.4	0
322	The Use of Proteomics in Urological Research. <i>EAU Update Series</i> , 2005, 3, 171-179.	0.5	5
323	The Role of Genetic Instability in the Pathogenesis and Progression of Urothelial Carcinoma. <i>EAU Update Series</i> , 2005, 3, 180-188.	0.5	0
324	Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. <i>Urology</i> , 2005, 65, 1233-1237.	0.5	79

#	ARTICLE	IF	CITATIONS
325	Do Height-Related Variations in Insulin-Like Growth Factors Underlie the Associations of Stature with Adult Chronic Disease?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 213-218.	1.8	52
326	Serum Insulin-Like Growth Factor-I Is Positively Associated with Serum Prostate-Specific Antigen in Middle-Aged Men without Evidence of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 163-165.	1.1	19
327	Evaluation of the Clinical Benefit of Permixon and Tamsulosin in Severe BPH Patientsâ€”PERMAL Study Subset Analysis. <i>European Urology</i> , 2004, 45, 773-780.	0.9	63
328	Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL-Induced Apoptosis. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1712-1721.	3.1	50
329	Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. <i>Prostate</i> , 2004, 59, 304-310.	1.2	52
330	Screen-detected prostate cancer and the insulin-like growth factor axis: Results of a population-based case-control study. <i>International Journal of Cancer</i> , 2004, 108, 887-892.	2.3	51
331	Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. <i>Urology</i> , 2004, 64, 317-322.	0.5	12
332	Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. <i>Human Pathology</i> , 2004, 35, 1385-1391.	1.1	66
333	Less is more: artificial intelligence and gene-expression arrays. <i>Lancet, The</i> , 2004, 364, 2003-2004.	6.3	6
334	The Survival Effect of Prolactin on PC3 Prostate Cancer Cells. <i>European Urology</i> , 2003, 43, 301-308.	0.9	37
335	Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. <i>Contemporary Clinical Trials</i> , 2003, 24, 272-282.	2.0	118
336	Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. <i>International Journal of Cancer</i> , 2003, 105, 484-490.	2.3	73
337	Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. <i>BJU International</i> , 2003, 91, 331-336.	1.3	44
338	Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. <i>Oncogene</i> , 2003, 22, 8699-8706.	2.6	127
339	Endothelin and Skeletal Metastases in Hormone-Refractory Prostate Cancer. <i>European Urology Supplements</i> , 2003, 2, 15-19.	0.1	2
340	Early diagnosis and surgical management of prostate cancer. <i>Cancer Treatment Reviews</i> , 2003, 29, 151-160.	3.4	23
341	Who can best recruit to randomized trials?. <i>Journal of Clinical Epidemiology</i> , 2003, 56, 605-609.	2.4	68
342	Are dietâ€”prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-1 and IGFBP-3 in healthy middle-aged men. <i>British Journal of Cancer</i> , 2003, 88, 1682-1686.	2.9	123

#	ARTICLE	IF	CITATIONS
343	Ethics of clinical trials from bayesian perspective: Randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer. BMJ: British Medical Journal, 2003, 326, 1456-1456.	2.4	2
344	The Molecular Staging of Prostate Cancer. , 2003, , 793-809.		0
345	Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks. Clinical Cancer Research, 2003, 9, 4172-7.	3.2	71
346	Staging in prostate cancer. Expert Review of Anticancer Therapy, 2002, 2, 48-58.	1.1	0
347	Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study * Commentary: presenting unbiased information to patients can be difficult. BMJ: British Medical Journal, 2002, 325, 766-770.	2.4	461
348	Comparison of a Phytotherapeutic Agent (Permixon) with an α -Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study. European Urology, 2002, 41, 497-507.	0.9	147
349	Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Research, 2002, 62, 1619-23.	0.4	203
350	Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. , 2000, 42, 18-25.		62
351	NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. Journal of Urology, 2000, 163, 630-633.	0.2	56
352	STAGING OF PROSTATE CANCER USING 3-DIMENSIONAL TRANSRECTAL ULTRASOUND IMAGES: A PILOT STUDY. Journal of Urology, 1999, 162, 1318-1321.	0.2	35
353	The immunohistochemical detection of cripto-1 in benign and malignant human bladder. , 1998, 185, 108-111.		10
354	Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. , 1998, 37, 223-229.		75
355	The Use of Flow Cytometry and RT-PCR in the Detection of Circulating PSA-Positive Cells in Prostate Cancer. , 1998, 92, 215-226.		4
356	Prostate. Current Opinion in Urology, 1996, 6, U111-U115.	0.9	0
357	Comparison of phytotherapy (Permixon [®]) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. , 1996, 29, 231-240.		294
358	Comparison of phytotherapy (Permixon [®]) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. , 1996, 29, 231.		1
359	Comparison of phytotherapy (Permixon [®]) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. , 1996, 29, 231.		10
360	Transrectal ultrasound guided needle electromyography of the urethral sphincter in males. Neurourology and Urodynamics, 1995, 14, 359-363.	0.8	4